News

Inhaling vaporized cannabis does not improve breathlessness or exercise endurance in patients with advanced chronic obstructive pulmonary disease (COPD), according to a small Canadian study. The study reporting the findings, “Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced COPD: A randomized controlled…

The U.S. Food & Drug Administration’s Pulmonary Allergy Drugs Advisory Committee voted that the risk-benefit profile of GSK’s mepolizumab was not adequate to support its approval as an add-on treatment for reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who are on maximum corticosteroid-based…

Treatment of chronic obstructive pulmonary disease (COPD) with a minimally invasive investigative procedure called targeted lung denervation (TLD) is feasible, safe, and was found to improve lung function, according to researchers. Their study, “Long-term safety of bilateral targeted lung denervation in patients with COPD,” was published in…

Psychological distress, even at low or moderate levels, increases the risk of arthritis, cardiovascular disease, and chronic obstructive pulmonary disease (COPD), researchers have found. This finding was reported in the study, “The effects of psychological distress and its interaction with socioeconomic position on risk of developing…

Consistent support from healthcare professionals, interaction with peers, and regular exercise can help people with chronic obstructive pulmonary disease (COPD) remain physically active over the long-term, a systematic review of multiple studies shows. The report identifies both barriers and beneficial elements for physical…

The U.S. Food and Drug Administration (FDA) has approved Pulmonx’s Zephyr Endobronchial Valve, a device designed to treat patients with severe emphysema who experience difficulty breathing. Emphysema is a type of chronic obstructive pulmonary disease (COPD) that results from damage to the alveoli, the small air sacs in…

A new clinical trial being conducted in the United Kingdom is recruiting participants to study the early stages of chronic obstructive pulmonary disease (COPD), and identify people at risk of developing the disease. This will be the first study to track changes in lung function over time before COPD…

Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with chronic obstructive pulmonary disease (COPD). The ongoing two-part Phase 2 trial, called SG015 (2017-003679-75), is evaluating the safety and effectiveness of SNG001 to prevent acute worsening of COPD symptoms…

Inhaled corticosteroids, which are typically used to treat common respiratory diseases such as chronic obstructive pulmonary disease (COPD), are associated with increased bacterial infections and can lead to worse health outcomes, a study in mice has found. Most exacerbations experienced by patients with asthma and COPD are caused by viral infections.

Pulmatrix‘s branded generic of Spiriva HandiHaler, called PUR0200, was shown to promote similar improvements in lung function in patients with chronic obstructive pulmonary disease (COPD), but at significantly lower doses than Spiriva, according to a Phase 1 clinical trial. The study reporting the findings is titled “The pharmacokinetics,…